Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.

Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, Rollinson S, Rawstron AC, Rees-Unwin KS, Li C, Munshi NC, Anderson KC, Morgan GJ.

Clin Cancer Res. 2004 Sep 1;10(17):5692-701.

2.

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL.

Blood. 1998 Nov 1;92(9):3025-34.

3.

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A.

Int J Oncol. 1999 Dec;15(6):1205-12.

PMID:
10568829
4.

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.

Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr.

Blood. 2003 Mar 15;101(6):2374-6. Epub 2002 Nov 14.

5.

A molecular study of the t(4;14) in multiple myeloma.

Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ.

Br J Haematol. 2002 Aug;118(2):514-20.

PMID:
12139740
6.

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM.

Blood. 2003 Feb 15;101(4):1520-9. Epub 2002 Oct 3.

7.

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK.

Blood. 2000 Feb 1;95(3):992-8.

8.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
9.

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.

Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Slovak ML, Liu X, Luo J, Yen Y.

Mol Cancer Ther. 2005 May;4(5):787-98.

10.

[Detection of IgH-MMSET fusion gene in multiple myeloma patients and its significance].

Jiang H, Hou J, Chen YB, Ding SQ.

Zhonghua Xue Ye Xue Za Zhi. 2003 Oct;24(10):515-8. Chinese.

PMID:
14690579
11.

Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.

Intini D, Fabris S, Storlazzi T, Otsuki T, Ciceri G, Verdelli D, Lombardi L, Rocchi M, Neri A.

Br J Haematol. 2004 Aug;126(3):437-9. No abstract available.

PMID:
15257719
12.

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).

Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A.

Br J Haematol. 2001 Aug;114(2):362-4.

PMID:
11529856
13.

Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.

Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT, Neri A.

Cancer Res. 2000 Aug 1;60(15):4058-61.

14.

Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.

Chandesris MO, Soulier J, Labaume S, Crinquette A, Repellini L, Chemin K, Malphettes M, Fieschi C, Asli B, Uzunhan Y, Fermand JP, Bories JC, Arnulf B.

Br J Haematol. 2007 Feb;136(4):609-14.

PMID:
17223917
15.

Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.

Hudlebusch HR, Theilgaard-Mönch K, Lodahl M, Johnsen HE, Rasmussen T.

Br J Haematol. 2005 Sep;130(5):700-8.

PMID:
16115125
16.

FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).

Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M.

Eur J Haematol. 2009 Nov;83(5):471-6. doi: 10.1111/j.1600-0609.2009.01312.x. Epub 2009 Jul 6.

PMID:
19594619
17.

Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.

Martin LD, Harizanova J, Righolt CH, Zhu G, Mai S, Belch AR, Pilarski LM.

Genes Chromosomes Cancer. 2013 Jun;52(6):523-37. doi: 10.1002/gcc.22049. Epub 2013 Mar 5.

PMID:
23460268
18.

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.

Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A.

Oncogene. 2001 Jun 14;20(27):3553-62.

19.

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.

Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S, Merlini G, Neri A.

Am J Pathol. 2001 May;158(5):1599-603.

20.

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.

Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK.

Blood. 2003 Jul 15;102(2):772-3. No abstract available.

Supplemental Content

Support Center